



European Medicines Research Training Network

EMTRAIN PhD Workshop 2014

New Horizons for Drug Development

11-14 May 2014

UCB, Braine-l'Alleud, Belgium



EMTRAIN PhD Workshop, 2014

New Horizons for Drug Development



Day 1 Sunday 11th of May 2014 – Grand Hotel Waterloo

11.00-11.30	Welcome and introduction Armel Stockis, UCB
11.30-12.00	EMTRAIN, role of PPP-PhDs. Anita Aperia, Professor Karolinska Intitutet
12.00-12.45	Lunch
12.45-13.30	The process of drug discovery and development Mike Hardman, Astra Zeneca
13.30-14.15	Partnerships in Biomedical Research Jeff Kipling, R&D Policy & Scientific Affairs, GSK
14.15-14.45	Coffee break
14.45-16.15	Student Presentations
16.15-18.15	Drug discovery game Keith Williams, KW Drug Development Ltd
18.15-18.30	Free time
18.30-19.30	Pre-dinner interactive session
19.30-	Dinner at Grand Hotel Waterloo

Day 2 Monday 12th of May 2014– UCB, Braine-l'Alleud

8.00	Bus pick-up at hotel for transfer to UCB
8:30-8:45	Welcome to UCB - housekeeping Armel Stockis
8.45-9.15	Introduction to UCB Jean-Christophe Donck, Global Site Facilities & Workplace Development, UCB
9.15-10.00	Preclinical drug development (small molecules and biologics), US and European experiences, contemporary and future issues Peter Theil, Non-clinical development, UCB
10.00-10.30	Coffee break
10.30-11.15	Intellectual property and scientific disclosure Stephane Drouin, Intellectual Property Group, UCB
11.15-12.30	Student Presentations
12.30-13.30	Lunch
13.30-14.15	A discovery story - Sclerostin, from gene to osteoporosis drug Adrian Moore, Research Immunology, UCB
14.15-15.00	Ethics 1 - Is research with animals necessary for scientific development and medical knowledge? Ethics, attitudes and decisions. Anne Christine Eklöf, Department of Comparative Medicine, Karolinska University Hospital
15.00-15.30	Coffee break
15.30-16.15	Ethics 2 - Good clinical practice and ethical standards in clinical research Ingrid Klingmann, European Forum for Good Clinical Practice
16.15-17.00	Ethics 3 - Current ethical debates in clinical research Jean-Marie Boyenaems, professor Free University of Brussels
17.00-18.00	Ethics group discussion
18.00-18.45	Innovative Medicines Initiative: A driving force for therapeutic innovation Nathalie Seigneuret, IMI Executive Office
19.00-19.30	Transfer
19.30-	Dinner – Basta restaurant

Day 3 Tuesday 13th of May 2014– UCB, Braine-l'Alleud

8.00	Bus pick-up at hotel for transfer to UCB
8.30-9.15	Student Presentations
9.15-10.00	Process analytical technology in the pharmaceutical world Edith Norrant, Pharmaceutical Innovation and Technology Development, UCB
10.00-10.30	Coffee break
10.30-12.30	Student Presentations
12.30-13.30	Lunch
13.30-15.00	Guided tour of the site, visit of biologics pilot plant and laboratories
15.00-15.45	IMI2 in the context of Horizon 2020 objectives and evolving R&D models and ecosystems Magda Chlebus, European Federation of Pharmaceutical Industries and Associations
15.45-16.15	Coffee break
16.15-17.15	Student Presentations
17.15-18.00	Regenerative Medicine, from bench to clinical application Christian Homsy, CEO Cardio3 Biosciences
18.00-18.45	Discovery of levetiracetam, the first SV2A ligand for the treatment of epilepsy Henrik Klitgaard, Research Neurosciences, UCB
18.45-21.30	Pre-dinner speaker - Armel Stockis, UCB Refreshments and BBQ at the Farm (UCB)
21.30-22.00	Transfer to Grand Hotel Waterloo

Day 4 Wednesday 14th of May 2014– UCB, Braine-l'Alleud

9.00	Bus pick-up at hotel for transfer to UCB
9.30-10.15	Innovation in drug delivery to the benefit of patients Jørgen Dirach, Novo Nordisk
10.15-11.00	Vaccines research and innovation Philippe Denoel, External R&D & Open Innovation, GSK Vaccines
11.00-11.30	Coffee break
11.30-12.15	Marie Curie postdoctoral funding actions Yiannis Vacondios, European Commission, Research Executive Agency
12.15-12.45	General discussion and student feedback session
12.45-13.00	Final remarks
13.00-	<i>Lunch and departure</i>